Seven Fleet Capital Management LP bought a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) during the 2nd quarter, Holdings Channel reports. The fund bought 411,065 shares of the company’s stock, valued at approximately $711,000. Seven Fleet Capital Management LP owned approximately 0.26% of Entero Therapeutics at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ENTO. Virtu Financial LLC bought a new stake in Entero Therapeutics in the third quarter valued at $59,000. GSA Capital Partners LLP purchased a new stake in shares of Entero Therapeutics in the 2nd quarter worth about $65,000. Persistent Asset Partners Ltd purchased a new stake in shares of Entero Therapeutics in the 2nd quarter worth about $198,000. ADAR1 Capital Management LLC bought a new stake in shares of Entero Therapeutics during the 2nd quarter valued at about $3,642,000. Finally, Elmind Capital LP bought a new stake in shares of Entero Therapeutics during the 2nd quarter valued at about $363,300,000. Hedge funds and other institutional investors own 12.30% of the company’s stock.
Entero Therapeutics Price Performance
Shares of NASDAQ ENTO opened at $4.06 on Thursday. Entero Therapeutics, Inc. has a 1 year low of $0.32 and a 1 year high of $5.84. The company’s 50-day moving average is $3.82 and its 200 day moving average is $3.42. The stock has a market capitalization of $6.45 million, a P/E ratio of -2.40 and a beta of 1.19.
Entero Therapeutics Profile
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical?stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility?related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
Read More
- Five stocks we like better than Entero Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding ENTO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report).
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
